As of May, 8 Inogen, Inc. (INGN) EPS Estimated At $0.27

April 16, 2018 - By Elizabeth Jones

Inogen, Inc. (NASDAQ:INGN) Corporate Logo
Big Money Sentiment decreased to 1.18 in 2017 Q4. It has change of 0.02, from 2017Q3’s 1.2. The ratio worsened due to Inogen, Inc. positioning: 19 sold and 68 reduced. 37 funds bought stakes and 66 increased stakes. Investors holded 20.61 million in 2017Q3 but now own 20.27 million shares or 1.65% less.
Invesco invested 0.01% of its capital in Inogen, Inc. (NASDAQ:INGN). Bnp Paribas Arbitrage Sa invested 0% in Inogen, Inc. (NASDAQ:INGN). Amundi Pioneer Asset Mgmt has 0.01% invested in Inogen, Inc. (NASDAQ:INGN). Ameriprise Financial stated it has 0.01% of its capital in Inogen, Inc. (NASDAQ:INGN). Tci Wealth holds 21 shs or 0% of its capital. Voya Invest Mngmt Limited Liability reported 0% of its capital in Inogen, Inc. (NASDAQ:INGN). Geode Ltd Liability Corp stated it has 155,022 shs or 0.01% of all its holdings. Glob X Management Co Lc invested in 0% or 300 shs. Moreover, Campbell & Co Investment Adviser Ltd Liability Company has 0.39% invested in Inogen, Inc. (NASDAQ:INGN). Prudential Financial reported 185,709 shs. Thompson Davis And has 0.04% invested in Inogen, Inc. (NASDAQ:INGN). Millennium Mngmt Limited Liability Company holds 271,928 shs or 0.04% of its capital. State Teachers Retirement System invested 0.01% of its capital in Inogen, Inc. (NASDAQ:INGN). Los Angeles Cap Mgmt And Equity holds 28,507 shs or 0.02% of its capital. The New York-based Pinebridge Invests Ltd Partnership has invested 0.02% in Inogen, Inc. (NASDAQ:INGN).

Investors wait Inogen, Inc. (NASDAQ:INGN)’s quarterly earnings on May, 8., according to Faxor. Analysts predict 0.00 % diference or $0.27 from the $0.27 EPS from 2017. If reported the P/E will be 129.10 with $5.73 million profit. Wall Street now forecasts -12.90 % negative EPS growth despite Inogen, Inc. last quarter’s EPS of $0.31. INGN reached $139.43 on during the last trading session after $0.51 change.Inogen, Inc. has 159,159 shares volume, 16.34% up from normal. INGN is uptrending and has moved 59.63% since April 17, 2017. INGN outperformed the S&P500 by 48.08%.

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

In total 4 analysts cover Inogen (NASDAQ:INGN). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:INGN)’s analyst reports since November 8, 2017 according to StockzIntelligence Inc. On Tuesday, February 20 PiperJaffray upgraded Inogen, Inc. (NASDAQ:INGN) to “Overweight” rating. The stock rating was maintained by Leerink Swann with “Buy” on Wednesday, November 8. On Wednesday, November 8 the stock of Inogen, Inc. (NASDAQ:INGN) has “Buy” rating given by Needham. On Tuesday, February 20 Piper Jaffray upgraded the shares of INGN in report to “Buy” rating. In Friday, April 13 report Needham maintained the stock with “Buy” rating. On Wednesday, February 28 Needham maintained the shares of INGN in report with “Buy” rating.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.The company has $2.96 billion market cap. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.The P/E ratio is 145.24. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

Inogen, Inc. (NASDAQ:INGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.